K. Jackson

发表

N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neu

G. Marek, K. Perry, J. Witkin, 2011, Journal of Pharmacology and Experimental Therapeutics.

A population PK model for citalopram and its major metabolite, N-desmethyl citalopram, in rats

N. Vélez de Mendizábal, R. Bies, S. Swanson, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin

Suzanne F. Jones, H. Burris, J. Infante, 2015, Investigational New Drugs.

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis.

S. Ball, K. Reich, A. Blauvelt, 2018, The Journal of investigative dermatology.

Pharmacokinetics, Metabolism, and Excretion of the Glycogen Synthase Kinase-3 Inhibitor LY2090314 in Rats, Dogs, and Humans: A Case Study in Rapid Clearance by Extensive Metabolism with Low Circulating Metabolite Exposure

K. Cassidy, P. Kulanthaivel, R. Barbuch, 2013, Drug Metabolism and Disposition.

An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia

G. Borthakur, D. Rizzieri, L. Brail, 2016, Leukemia & lymphoma.

Exposure‐Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis

N. Vélez de Mendizábal, K. Reich, S. Friedrich, 2018, Journal of clinical pharmacology.

Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects

C. Brittain, S. Tauscher‐Wisniewski, J. McColm, 2017, British journal of clinical pharmacology.

Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)

N. Vélez de Mendizábal, A. Paller, K. Papp, 2021, British journal of clinical pharmacology.

Neutrophil elastase inhibition in acute lung injury: Results of the STRIVE study

G. Bernard, J. Vincent, A. Dmitrienko, 2004, Critical care medicine.

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

S. Mosolov, D. Schoepp, Lu Zhang, 2007, Nature Medicine.

Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants

K. Jackson, E. Gomez, T. Muram, 2017, BioDrugs.

Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A)

L. Mallbris, F. Zhao, K. Callis Duffin, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies

G. Dawson, R. Mohs, C. Harmer, 2016, Neuropsychopharmacology.

A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies

G. Dawson, R. Mohs, C. Harmer, 2016, Neuropsychopharmacology.

Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects

Steven C. R. Williams, A. Schwarz, M. Mehta, 2018, Psychopharmacology.

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

B. Kinon, S. Kollack-Walker, O. Osuntokun, 2011, Journal of clinical psychopharmacology.

Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases

David A. Evans, C. Felder, L. Broad, 2018, Neuropharmacology.

Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects

Steven C. R. Williams, A. Schwarz, M. Mehta, 2018, Psychopharmacology.

Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants

K. Jackson, E. Gomez, T. Muram, 2017, BioDrugs.

Effects of a novel mGlu2/3 receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid

R. Dean, K. Perry, D. McKinzie, 2012, Psychopharmacology.

Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence.

R. Mohs, A. Post, R. Anton, 2016, Alcoholism, clinical and experimental research.

Corrigenda: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

S. Mosolov, D. Schoepp, Lu Zhang, 2007, Nature Medicine.

Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.

Kimberley Jackson, Ivelina Gueorguieva, Jenny Y Chien, 2010, British journal of clinical pharmacology.

Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study.

Xiang Chen, C. Payne, K. Jackson, 2023, Advances in therapy.

Effects of a novel mGlu2/3 receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid

R. Dean, K. Perry, D. McKinzie, 2011, Psychopharmacology.